Medicare Coverage Of PET Pharmaceutical Agents Needs Revamp, Industry Says

A broad range of stakeholders is asking CMS to remove national non-coverage language for newly approved radiopharmaceuticals used in positron emission tomography to allow speedier access to new tools for diagnosing Alzheimer’s and other diseases.

More from Medicare

More from Government Payers